Smith & Nephew and J&J orthopaedics merger talks collapse over CEO role

what happened

According to the Financial Times, talks to combine Johnson & Johnson's orthopaedics division with Smith & Nephew fell apart at a late stage. Both companies had agreed the main financial terms and structure of the transaction, but a dispute over who would run the enlarged group proved impossible to settle. The London-listed company refused to accept its former chief executive leading the business and said it would agree only if its current boss, Deepak Nath, stayed in the role. A Smith & Nephew spokesperson declined to comment, and J&J could not be reached outside business hours. Reuters cited the FT report but said it could not independently verify it.

The proposed deal would have created a medical technology company worth $34 billion. J&J's hip and knee replacement unit was valued at as much as $22 billion, almost double Smith & Nephew's market capitalisation of £9.4 billion ($12.58 billion).

why it matters

The collapse shows that large medtech deals can stall over management questions even when price and structure are agreed. J&J announced in October 2025 that it would separate the orthopaedics business into a standalone company called DePuy Synthes. The unit was reportedly seeking about $20 billion, and while private equity has shown interest, no deal has materialised. For investors, it highlights how uncertain valuations of such assets remain.

market impact

Smith & Nephew, J&J: the failed talks remove expectations of a medtech merger and weigh on both companies' shares

tags

instruments